Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 104Gastrointestinal 52Breast 26Sarcoma 20Gynecologic 19Head & Neck 16CNS 11Endocrine 8Other solid neoplasm 7Tumor-Agnostic 6Genitourinary 5NET 2Dermatologic 2

Conditions

Melanoma 2

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × anlotinib × Dermatologic × Clear all
NCT06327698 2024-03-25

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Hunan Cancer Hospital

Phase 2 Not yet recruiting
30 enrolled
Dermatologic

Melanoma

NCT04979585 2021-08-03

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

The First Hospital of Jilin University

Phase 2 Unknown
66 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡